← Leaderboards
John M. Pagel
Fred Hutchinson Cancer Research Center
$5,647,981
Attributed
$5,987,675
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–18$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$5,987,675 · 10
By mechanism
P01$3,167,237 · 2
R01$2,124,724 · 2
K08$668,250 · 1
M01$27,464 · 5
Top collaborators
- Brenda Marie Sandmaier1 shared
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- Oliver W. Press$23,607,906
- Brenda Marie Sandmaier$22,185,663
- Janell Baldwin$1,701,369
- David G Maloney$3,575,748
- Marco B Mielcarek$5,038,080
Others in their field
Top investigators on “Radiotracer”
- Robert H Mach · Wake Forest University$39,562,505
- Simon R Cherry · University Of California Los Angeles$17,948,135
- Joel Synes Perlmutter · Washington University$16,457,601
- Gwenn S Smith · Long Island Jewish Medical Center$16,008,680
- Richard E Carson · Yale University$15,174,693
- Rajesh Narendran · Columbia University Health Sciences$15,115,382
Research focus
RadiotracerMonoclonal AntibodiesPtprc GeneRadioimmunotherapyRadiolabeledAntibodiesCellsRegimenDoseLiverDisease RemissionAllogenicMarrowHematopoieticTransplantationOrganLeukemiaRadiationToxic EffectResponseSiteT-LymphocyteLungLeukemia, Myelocytic, Acute
Grant awards (28)
Core B: Pharmaceutical Production$141,712
P01 · FY2018 · CA · contact PI
Core B: Pharmaceutical Production$443,320
P01 · FY2017 · CA · contact PI
Core B: Pharmaceutical Production$443,320
P01 · FY2016 · CA · contact PI
Core B: Pharmaceutical Production$438,669
P01 · FY2015 · CA · contact PI
Radioimmunotherapy for Leukemia$279,230
P01 · FY2015 · CA · contact PI
Core B: Pharmaceutical Production$322,320
P01 · FY2014 · CA · contact PI
Radioimmunotherapy for Leukemia$267,368
P01 · FY2014 · CA · contact PI
Alpha Radioimmunotherapy for Lymphoma Treatment$679,389
R01 · FY2013 · CA
Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot$332,990
R01 · FY2013 · CA · contact PI
Radioimmunotherapy for Leukemia$264,637
P01 · FY2013 · CA · contact PI
Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot$38,657
R01 · FY2013 · CA · contact PI
Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot$354,244
R01 · FY2012 · CA · contact PI
Radioimmunotherapy for Leukemia$282,711
P01 · FY2012 · CA · contact PI
Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot$354,244
R01 · FY2011 · CA · contact PI
Radioimmunotherapy for Leukemia$283,950
P01 · FY2011 · CA · contact PI
Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot$365,200
R01 · FY2010 · CA · contact PI
Radioimmunotherapy of CD20+ Lymphomas & CD45+Leukemias$133,650
K08 · FY2008 · CA · contact PI
Radioimmunotherapy of CD20+ Lymphomas & CD45+Leukemias$133,650
K08 · FY2007 · CA · contact PI
RADIOLABELED BC8, FLU, TBI AND PBSC TRANSPLANT FOR ELDERLY AML OR MDS PATIENTS$1,066
M01 · FY2007 · RR · contact PI
Radioimmunotherapy of CD20+ Lymphomas & CD45+Leukemias$133,650
K08 · FY2006 · CA · contact PI
RADIOLABELED BC8, FLUDARABINE, TBI FOLLOWED BY PBSC TRANSPLANT FOR ADVANCED AML$2,481
M01 · FY2006 · RR · contact PI
RADIOLABELED BC8, FLU, TBI AND PBSC TRANSPLANT FOR ELDERLY AML OR MDS PATIENTS$1,655
M01 · FY2006 · RR · contact PI
Radioimmunotherapy of CD20+ Lymphomas &CD45+Leukemias$133,650
K08 · FY2005 · CA
PHASE I STUDY: ELDERLY PATIENTS WITH MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROM$17,828
M01 · FY2005 · RR
RADIOLABELED BC8 (ANTI-CD45) ANTIBODY TREATMENT FOR ACUTE MYELOID LEUKEMIA$2,139
M01 · FY2005 · RR
A FEASIBILITY TRIAL COMBINING RADIOLABELED BC8 ANTIBODY WITH FLUDARABINE$1,427
M01 · FY2005 · RR
Radioimmunotherapy of CD20+ Lymphomas &CD45+Leukemias$133,650
K08 · FY2004 · CA
Phase II study for acute myelogenous leukemia in first$868
M01 · FY2004 · RR